Novo Nordisk A/S (NYSE:NVO) is among the many most worthwhile healthcare shares to purchase. On January 26, BMO Capital lifted the worth goal on Novo Nordisk A/S (NYSE:NVO) to $57 from $47 and maintained a Market Carry out score. The agency highlighted flat prescription developments (TRx) for the corporate’s weight reduction candidate Wegovy within the fourth quarter of 2025 relative to the third quarter.
BMO Capital lowered its 2025 Wegovy gross sales estimate to DKK 77.8 billion, down from DKK 79.8 billion, in contrast with a consensus forecast of DKK 78.4 billion. Regardless of favorable tailwinds, together with the CVS exclusivity settlement, pressures just like the anticipated QoQ pricing live on, the agency famous. That stated, BMO Capital estimates a comparatively flat 2026 U.S. prescription quantity in contrast with 2025 ranges, which might result in detrimental YoY U.S. internet gross sales progress.
Cherries/Shutterstock.com
Three days earlier, Reuters reported that the corporate’s Wegovy drug was prescribed over 18,000 instances within the U.S. through the first full week following its launch. The report cited James Gordon from Barclays, who stated,
“The early oral Wegovy launch knowledge may be very robust, albeit in a now much better established weight problems market versus constructing the weight problems market.”
Novo Nordisk A/S (NYSE:NVO) is a Denmark-based firm that focuses on pharmaceutical merchandise. Based in 1923, the enormous operates by means of two segments: Diabetes and Weight problems Care and Uncommon Illness.
Whereas we acknowledge the potential of NVO as an funding, we imagine sure AI shares supply better upside potential and carry much less draw back danger. For those who’re in search of a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.
READ NEXT: The Finest and Worst Dow Shares for the Subsequent 12 Months and 10 Unstoppable Shares That May Double Your Cash.
Disclosure: None.
